Results 141 to 150 of about 22,968 (195)

Dual CDK4/6-PI3K/mTOR inhibition reinforces cytostatic programs and tumor control in preclinical models of primary and metastatic osteosarcoma. [PDF]

Neoplasia
Barghi F, Saadatzadeh MR, Dobrota EA, Shannon HE, Bailey BJ, Young C, Malko R, Justice R, Riyahi N, Davis C, Bijangi-Vishehsaraei K, Kreklau K, Stevens LK, Koenig J, Sulayman S, Liu S, Wan J, Trowbridge MA, Coy K, Kennedy FM, Sinn AL, Just M, Jackson KW, Sandusky G, Wurtz LD, Collier CD, Mitchell D, Seiden EE, Greenfield EM, Doud E, Mosley A, Angus SP, Ferguson MJ, Pandya PH, Pollok KE.   +34 more
europepmc   +1 more source

Integration of pre‑existing cardiovascular comorbidity into CDK4/6 inhibitor selection for breast cancer. [PDF]

Ther Adv Drug Saf
Park C, Kim K, Abifaraj NB, Bryant SD, Heo JH.   +4 more
europepmc   +1 more source

Biomarkers of primary and secondary resistance to cyclin dependent kinases 4 and 6 inhibitors in metastatic estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer: a narrative review. [PDF]

Transl Breast Cancer Res
Stravodimou A, Voutsadakis IA.
europepmc   +1 more source

Regulation of the immune CD155-CD226-TIGIT axis by cyclin D-CDK4/6. [PDF]

Proc Natl Acad Sci U S A
Fassl A, Palacios Espinoza M, Butter D, Kolodziejczyk A, Seehawer M, Hill C, Ning X, Branigan TB, Peñailillo J, Saengboonmee C, Jadhav H, Charbonnier LM, Waks AG, Strawser C, McDonnell DP, Shapiro GI, Tolaney SM, Polyak K, Sammons S, Wucherpfennig KW, Sicinski P.   +20 more
europepmc   +1 more source

Efficacy and Mechanisms of CDK4/6 Inhibitors in Breast Cancer: Advancing Targeted Therapeutic Strategies. [PDF]

Oncol Res
Patwekar M, Patwekar F, Kari ZA, Zain MRAM, Mohammed A, Sharma R.   +5 more
europepmc   +1 more source

Continuous Flow Paper Spray Ionization Mass Spectrometry for In-Depth Characterization of Anticancer Drugs in Tissues: Addressing Mass Spectral Complexity. [PDF]

J Am Soc Mass Spectrom
Basuri P, Klinghammer K, Klein O, Volmer DA.   +3 more
europepmc   +1 more source

TGFβ signaling promotes cell cycle progression and resistance to the CDK4/6 inhibitor palbociclib through SOX4 transcriptional modulation in breast cancer cells. [PDF]

Cell Death Dis
Ali MM, Itoh Y, Badji AMP, Gallant S, Tsirigoti C, Bai Y, Filipek-Górniok B, Miyazawa K, Heldin CH, Moustakas A.   +9 more
europepmc   +1 more source

Molecular and immune biomarker testing in squamous-cell lung cancer: Effect of current and future therapies and technologies [PDF]

, 2018
Bradley, Jeffrey D, et al,
core   +1 more source